Next Phase Newsletter

By Nono Hu, Director of Marketing, LSN

With RESI on MaRS coming up next week, the LSN team are getting ready to head to Canada’s hub of healthcare innovation, Toronto!  With over 300 healthcare companies supported by MaRS Discovery District, we’re looking forward to hosting RESI in this rising biomedical innovation scene.

LSN would like to present the RESI on MaRS Program Guide.  If you’re planning your day in Toronto and want to see full lists of the speakers, RESI Innovation Challenge participants, exhibitors and sponsors you could meet, look no further!

By Cole Bunn, Senior Research Analyst, LSN

As tech continues its foray into healthcare, we are seeing a variety of different digital solutions for just about every segment of the healthcare industry. The relatively nascent nature of this sector has entrepreneurs and investors still working to figure out the most effective ways to work their way into large healthcare systems or efficiently reach consumers and add value.

Moderated by Dennis Giokas, Chief Technology Officer, Canada Health Infoway this session will feature:

• Tom Hawes, Managing Director, Sandbox Industries
• Shurjeel Choudhri, Senior VP & Head, Medical & Scientific Affairs, Bayer Healthcare
• Jean-Francois Pariseau, Partner, Healthcare Fund, BDC
• Dennis Depenbusch, Director, New Ventures Initiative, BCBSKS

This panel will provide a unique perspective on the digital health investment landscape with a varied lineup of organizations who are putting money to work in this burgeoning area of healthcare, including pharma, payers and a government VC arm.

By registering for RESI on MaRS, you’ll be able to listen to the early digital health panel live in person, interact with the investors and experience numerous opportunities to expand your network in the life sciences.

By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

For the first time ever, RESI is taking the Innovation Challenge to MaRS Discovery District in Toronto, Canada on June 23. The competition will feature 30 handpicked early stage innovators from MaRS and across North America.

From a competitive pool of applicants, these entrepreneurs have been selected by LSN’s scientific validation team based on their scientific merit and “investor readiness.” The 30 companies bring together cutting-edge innovations across healthcare IT, biotech, medical device, and diagnostics.

Meaningful connection is key to RESI Innovation Challenge. Instead of a traditional 15-minute pitch contest, the companies will receive a presentation space in the exhibition hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. LSN has found repeatedly that companies presenting in this venue interact with more investors—and with more meaningful dialogues.

To add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital that was invested will be tallied up and the top three winners will be featured in our RESI newsletter recap that will go out to LSN’s 23,000 newsletter readership.

• First Prize: Complimentary tickets to 3 RESI Conference Series events of your choice (2 tickets per event)
• Second Prize: Complimentary tickets to 2 RESI Conference Series events of your choice (2 tickets per event)
• Third Prize: Complimentary tickets to 1 RESI Conference Series event of your choice (2 tickets)

Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!

By Cole Bunn, Senior Research Analyst, LSN

As we approach our third RESI event of 2016, LSN prides itself on continuing to foster an environment that allows entrepreneurs to effectively engage with investors, strategic partners and other key stakeholders that have the ability to move the needle in their venture. The value in robust networking/partnering coupled with first-hand insight from veteran investors and industry leaders, for diagnostic entrepreneurs is clear.

Moderated by Tom Miller, Managing Partner, GreyBird Ventures, this session will feature:

• Nicola Urbani, Investment Director, Emerillon Capital
• John Steuart, Managing Director, Steuart Ventures
• Kathryn Deuchars, Director, Ontario Personalized Medicine Network, Ontario Genomics
• Jeff Summer, SVP Business Development, Clinical Affairs & Genetics, LifeLabs

The investors on this panel will share their perspective and tactical guidance for shepherding a diagnostic at the early stages of development through the dynamic healthcare environment to an eventual exit.

By registering for RESI on MaRS, you’ll be able to listen to the early stage diagnostics panel live in person, and also experience numerous opportunities to expand your network in the life sciences and to learn more about the fundraising process.